Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 1998

View Archived Issues

Lepirudin more effective than heparin in preventing cardiac events in unstable angina

Greater renal protective effects with CGS-30440 than with ACE inhibitor

Cantab: six-month highlights

Antithrombotic and antiplatelet actions of combination ticlopidine/EGb-761 therapy

Ariad updates stockholders

ImClone Systems: Q2 1998 highlights

Interneuron: Q2 1998 highlights

Zeneca provides mid-year update of R&D pipeline

Vanguard Medica, Roche to collaborate on development of endothelin antagonist

Tropane analogues claimed for cocaine addiction by HHS

Fujisawa prepares new urea derivatives as 5-HT antagonists

RXR/RAR receptor modulators claimed by CIRD Galderma for skin and other disorders

New diagnostic agents described in patent literature by Schering AG

U.S. university researchers discover nucleoside analogues for EBV

Taisho and Nihon Nohyaku describe development of potential new antipsychotics at ACS meeting

WHI investigators design novel inhibitors of EGF receptor tyrosine kinase

DuPont presents XJ-304 and related compounds as ACAT inhibitors at ACS

Novel ACAT inhibitors from DuPont Pharmaceuticals debut at ACS meeting

Glaxo Wellcome describes hypoglycemic activity of PPAR ligand

New tool now available for studying neurotensin receptors

Novel antitumor macrocyclic lactones available for licensing from NIH

Licensing opportunity from the NIH: carrier for conjugate vaccines

Novel WHI compound inhibits 5-LO translocation in mast cells

FDA approves Atridox: new patient-friendly treatment option for periodontal disease

Radioiodinated phospholipid ether analogues useful for tumor imaging

Astra presents data on novel series of cPLA2 inhibitors

Potent and selective inhibitors of p56lck kinase developed at Celltech

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...